Mondrian Investment Partners LTD trimmed its holdings in shares of Innospec Inc. (NASDAQ:IOSP) by 17.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 67,640 shares of the specialty chemicals company’s stock after selling 14,667 shares during the period. Mondrian Investment Partners LTD’s holdings in Innospec were worth $4,775,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Schwab Charles Investment Management Inc. boosted its stake in Innospec by 5.7% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 167,152 shares of the specialty chemicals company’s stock valued at $11,801,000 after purchasing an additional 9,061 shares during the last quarter. GSA Capital Partners LLP lifted its holdings in shares of Innospec by 306.8% during the 3rd quarter. GSA Capital Partners LLP now owns 28,376 shares of the specialty chemicals company’s stock valued at $1,749,000 after buying an additional 21,401 shares during the period. Algert Global LLC lifted its holdings in shares of Innospec by 26.1% during the 3rd quarter. Algert Global LLC now owns 43,644 shares of the specialty chemicals company’s stock valued at $2,691,000 after buying an additional 9,022 shares during the period. California Public Employees Retirement System lifted its holdings in shares of Innospec by 15.6% during the 3rd quarter. California Public Employees Retirement System now owns 29,351 shares of the specialty chemicals company’s stock valued at $1,809,000 after buying an additional 3,951 shares during the period. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of Innospec by 64.5% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 7,232 shares of the specialty chemicals company’s stock valued at $446,000 after buying an additional 2,835 shares during the period. Institutional investors and hedge funds own 91.18% of the company’s stock.

In related news, Director Milton C. Blackmore sold 977 shares of the firm’s stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $73.67, for a total value of $71,975.59. Following the transaction, the director now directly owns 6,977 shares of the company’s stock, valued at approximately $513,995.59. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Brian Watt sold 440 shares of the firm’s stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $70.17, for a total value of $30,874.80. Following the completion of the transaction, the vice president now directly owns 30,730 shares in the company, valued at $2,156,324.10. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 24,366 shares of company stock worth $1,743,891. 2.02% of the stock is owned by insiders.

Several equities analysts have recently weighed in on the company. Zacks Investment Research cut Innospec from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. BidaskClub raised Innospec from a “sell” rating to a “hold” rating in a report on Wednesday, December 27th. Monness Crespi & Hardt cut Innospec from a “buy” rating to a “neutral” rating in a report on Thursday, November 9th. KeyCorp reissued an “overweight” rating on shares of Innospec in a report on Thursday, November 9th. Finally, ValuEngine raised Innospec from a “hold” rating to a “buy” rating in a report on Thursday, November 9th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $70.50.

Shares of Innospec Inc. (IOSP) traded up $0.35 during trading on Thursday, reaching $72.65. The company had a trading volume of 102,500 shares, compared to its average volume of 74,918. Innospec Inc. has a one year low of $54.10 and a one year high of $74.75. The company has a market cap of $1,745.15, a PE ratio of 20.12 and a beta of 1.21. The company has a current ratio of 2.24, a quick ratio of 1.35 and a debt-to-equity ratio of 0.30.

Innospec (NASDAQ:IOSP) last announced its earnings results on Tuesday, November 7th. The specialty chemicals company reported $1.00 EPS for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.15. Innospec had a return on equity of 15.05% and a net margin of 7.45%. The company had revenue of $332.40 million for the quarter, compared to analysts’ expectations of $309.40 million. During the same period last year, the firm earned $0.78 EPS. Innospec’s revenue for the quarter was up 61.8% compared to the same quarter last year. equities research analysts anticipate that Innospec Inc. will post 4.3 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.watchlistnews.com/innospec-inc-iosp-holdings-reduced-by-mondrian-investment-partners-ltd/1812434.html.

Innospec Profile

Innospec Inc is a specialty chemicals company engaged in developing, manufacturing, blending, marketing and supplying of specialty chemicals for use as fuel additives and ingredients for personal care, home care, agrochemical, mining and other applications and oilfield chemicals. The Company operates through four business segments: Fuel Specialties, Performance Chemicals, Oilfield Services and Octane Additives.

Want to see what other hedge funds are holding IOSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Innospec Inc. (NASDAQ:IOSP).

Institutional Ownership by Quarter for Innospec (NASDAQ:IOSP)

Receive News & Ratings for Innospec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innospec and related companies with MarketBeat.com's FREE daily email newsletter.